GLP-1 Market Size, Share, Trend, Revenue Report 2026 to 2035
What is GLP-1 Market Size?
Global GLP-1 Market Size is valued at USD 94.06 Bn in 2025 and is predicted to reach USD 216.12 Bn by the year 2035 at an 8.8% CAGR during the forecast period for 2026 to 2035.
GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035.
GLP-1 Market Key Takeaways:
|
The glucagon-like peptide-1 receptor (GLP1R) is a crucial target in treating type 2 diabetes and obesity, given its significant role in regulating blood sugar levels and appetite. GLP-1, a hormone produced in the gut, enhances insulin secretion from pancreatic beta cells in response to glucose, increases insulin expression, and reduces beta-cell apoptosis.
It also lowers glucagon secretion, slows stomach emptying, promotes satiety, and improves glucose disposal in peripheral tissues. Medications known as GLP-1 agonists, including exenatide, liraglutide, and semaglutide, activate the GLP1R, effectively lowering blood sugar levels and facilitating weight loss in individuals with type 2 diabetes.
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns. With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss. GLP-1 agonist medications, which target the GLP-1 receptor to regulate insulin, glucagon, and appetite, offer a promising therapeutic approach to these health challenges. As the prevalence of these metabolic disorders continues to rise, the GLP-1 receptor agonist market is set for substantial growth in the coming years.
Competitive Landscape
Some of the Key Players in GLP-1 Market:
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd.
- Novo Nordisk A/S
- PegBio Co., Ltd.
- Pfizer Inc.
- QL Biopharmaceutical Co., Ltd.
- Roche Holding AG
- Sanofi S.A.
- Sciwind Biosciences Co., Ltd.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Viking Therapeutics, Inc.
- Amgen Inc.
- BioLingus GmbH
- D&D Pharmatech Inc.
- Gmax Biopharm LLC
- Hanmi Pharmaceutical Co., Ltd.
- Vivani Medical, Inc.
- vTv Therapeutics Inc.
- Zealand Pharma A/S
- Altimmune, Inc.
- Structure Therapeutics Inc.
Market Segmentation:
The GLP-1 market is segmented by type of molecule, active compound used, type of glp-1 agonist drugs, type of agonist, route of administration, target indication. By type of molecule the market is segmented into biologics and small molecules, by active compound used market is categorized into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. By type of glp-1 agonist drugs market is categorized into long-acting glp-1 agonist and short-acting glp-1 agonist. By type of agonist the market is single-agonist, dual-agonist and tri-agonist, by route of administration market is categorized into oral and parenteral, by target indication market is categorized into Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
Semaglutide Segment is Expected to Drive the GLP-1 Market
The semaglutide segment is a key driver of growth in the GLP-1 receptor agonist market due to its effectiveness and popularity. Marketed as Ozempic and Wegovy, semaglutide has proven highly effective in lowering blood sugar levels in type 2 diabetes patients and promoting significant weight loss in individuals with obesity. Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise. Additionally, innovative formulations and administration methods, such as once-weekly injections and oral options, enhance patient convenience and adherence. Semaglutide also offers notable cardiovascular benefits, making it an attractive option for patients with type 2 diabetes and obesity who face increased heart disease risks.
The Obesity Segment is Growing at the Highest Rate in the GLP-1 Market.
The obesity segment is the fastest-growing area in the GLP-1 receptor agonist market due to several key factors. First, the global prevalence of obesity is rising, with over 40% of adults in the U.S. classified as clinically obese, driving demand for effective weight loss treatments like GLP-1 agonists. Additionally, regulatory approvals for drugs such as semaglutide (Wegovy) specifically for obesity treatment have expanded the patient population significantly. GLP-1 agonists have also shown strong efficacy in clinical trials, with patients achieving an average weight loss of 15-25%, further promoting rapid adoption. Moreover, increasing insurance coverage and affordability of these medications are enhancing patient access, facilitating their utilization in managing obesity.
Regionally, Asia-Pacific Led the GLP-1 Market.
The APAC region is leading the global GLP-1 receptor agonist market, characterized by rapid growth driven by countries such as China, Japan, and India. This expansion is fueled by a growing healthcare sector, a large target patient population, and significant unmet clinical needs for diabetes and obesity treatments. The rising prevalence of type 2 diabetes and obesity in these countries is increasing demand for effective GLP-1 agonist therapies. Additionally, major pharmaceutical companies are innovating and developing tailored solutions for the APAC market to meet these rising demands. Although specific market share data is limited, the APAC region is recognized as the fastest-growing and a key contributor to the overall GLP-1 receptor agonist market.
GLP-1 Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 94.06 Billion |
| Revenue Forecast In 2035 | USD 216.12 Billion |
| Growth Rate CAGR | CAGR of 8.8% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication, Dosing Frequency, Delivery System and Payer |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., QL Biopharmaceutical Co., Ltd., Roche Holding AG, Sanofi S.A., Sciwind Biosciences Co., Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Viking Therapeutics, Inc., Amgen Inc., BioLingus GmbH, D&D Pharmatech Inc., Gmax Biopharm LLC, Hanmi Pharmaceutical Co., Ltd., Vivani Medical, Inc., vTv Therapeutics Inc., Zealand Pharma A/S, Altimmune, Inc., Structure Therapeutics Inc. and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of GLP-1 Market -
GLP-1 Market by Type of Molecule -
- Biologic Peptide GLP-1 Agonists
- Small-Molecule Non-Peptide GLP-1 Agonists
GLP-1 Market by Active Compound Used -
- Semaglutide
- Tirzepatide
- Dulaglutide
- Liraglutide
- Lixisenatide
- Exenatide
- Orforglipron
- Retatrutide
- Survodutide
- Other Active Compounds
GLP-1 Market by Type of GLP-1 Agonist Drugs -
- Long-acting GLP-1 Agonist
- Short-acting GLP-1 Agonist
GLP-1 Market by Type of Agonist -
- Single agonist
- Dual agonist
- Tri-agonist
GLP-1 Market by Route of Administration-
- Oral
- Parenteral
GLP-1 Market by Target Indication-
- Alzheimer’s Disease
- Non-Alcoholic Steatohepatitis
- Obesity
- Sleep Apnea
- Type 2 Diabetes
GLP-1 Market By Dosing Frequency-
- Daily
- Weekly
- Monthly or Extended-Interval
GLP-1 Market By Delivery System-
- Disposable Pre-filled Pen
- Auto-Injector
- Pre-filled Syringe
- Oral Tablet / Capsule
GLP-1 Market By Payer-
- Retail Pharmacy – Commercial Insurance
- Retail Pharmacy – Government (Medicare / Medicaid)
- Specialty / Mail-Order Pharmacy
- Self-Pay
GLP-1 Market by Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
GLP-1 Market Size is valued at USD 94.06 Bn in 2025 and is predicted to reach USD 216.12 Bn by the year 2035.
GLP-1 Market is predicted to grow at a 8.8% CAGR during the forecast period for 2026-2035
AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Innogen Pharmaceutical Technology Co., Ltd. / Guangzhou Innogen Pharmaceutical Group Co., Ltd., Novo Nordisk A/S, PegBio Co., Ltd., Pfizer Inc., QL Biopharmaceutical Co., Ltd., Roche Holding AG, Sanofi S.A., Sciwind Biosciences Co., Ltd., Tonghua Dongbao Pharmaceutical Co., Ltd., Viking Therapeutics, Inc., Amgen Inc., BioLingus GmbH, D&D Pharmatech Inc., Gmax Biopharm LLC, Hanmi Pharmaceutical Co., Ltd., Vivani Medical, Inc., vTv Therapeutics Inc., Zealand Pharma A/S, Altimmune, Inc., Structure Therapeutics Inc. and Others
GLP-1 market is segmented by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication, Dosing Frequency, Delivery System and Payer are the key segment of GLP-1 Market.
North American region is leading the GLP-1 Market